Body mass index and risk of primary liver cancer: A meta-analysis of prospective studies

Oncologist

Volumn 17, Issue 11, 2012, Pages 1461-1468

  Wang, Yuqin ^a   Wang, Baochan ^a   Shen, Feng ^a   Fan, Jiangao ^a   Cao, Haixia ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Body mass index; Meta analysis; Primary liver cancer; Relative risk

Indexed keywords

ALPHA FETOPROTEIN;

ARTICLE; BODY MASS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; DATA EXTRACTION; DISEASE ASSOCIATION; EXPOSURE; FOLLOW UP; GENDER; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CANCER; LIVER CIRRHOSIS; META ANALYSIS; OBESITY; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY ANALYSIS;

BODY MASS INDEX; FEMALE; FIBROSIS; HEPATITIS B; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MALE; OBESITY; PROSPECTIVE STUDIES; RISK; RISK FACTORS; WEIGHT GAIN;

EID: 84869470152     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0066     Document Type: Article

References (51)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
2. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
3. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-2150.
4. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000;160:3227-3230.
5. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004; 127:S72-78.
6. Bosch FX, Ribes J, Diaz M et al. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004;127:S5-S16.
7. Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis 2007;11:191-207.
8. Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: A meta-analysis of cohort studies. Br J Cancer 2007;97:1005-1008.
9. Polesel J, Zucchetto A, Montella M et al. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol 2009;20:353-357.
10. Chen CL, Yang HI, Yang WS et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: A follow-up study in Taiwan. Gastroenterology 2008;135:111-121.
11. Jee SH, Yun JE, Park EJ et al. Body mass index and cancer risk in Korean men and women. Int J Cancer 2008;123:1892-1896.
12. Joshi S, Song YM, Kim TH et al. Socio-economic status and the risk of liver cancer mortality: A prospective study in Korean men. Public Health 2008;122: 1144-1151.
13. Ohishi W, Fujiwara S, Cologne JB et al. Risk factors for hepatocellular carcinoma in a Japanese population: A nested case-control study. Cancer Epidemiol Biomarkers Prev 2008;17:846-854.
14. Ohki T, Tateishi R, Sato T et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol 2008;6:459-464.
15. Veldt BJ, Chen W, Heathcote EJ et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008;47:1856-1862.
16. Batty GD, Barzi F, Huxley R et al. Obesity and liver cancer mortality in Asia: The Asia Pacific Cohort Studies Collaboration. Cancer Epidemiol 2009;33:469-472.
17. Inoue M, Kurahashi N, Iwasaki M et al. Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: A large-scale population- based cohort study of Japanese men and women (JPHC Study Cohort II). Cancer Causes Control 2009; 20:741-750.
18. Hart CL, Batty GD, Morrison DS et al. Obesity, overweight and liver disease in the Midspan prospective cohort studies. Int J Obes (Lond) 2010;34:1051-1059.
19. Nkontchou G, Bastard JP, Ziol M et al. Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. J Hepatol 2010;53: 827-833.
20. Arano T, Nakagawa H, Tateishi R, et al. Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients. Int J Cancer.
21. Borena W, Strohmaier S, Lukanova A et al. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer 2012;131:193-200.
22. Stroup DF, Berlin JA, Morton SC et al. Metaanalysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283:2008-2012.
23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
24. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992; 135:1301-1309.
25. Orsini NBR, Greenland S. Generalized least squares for trend estimation of summarized dose-response data. Stata J 2006;6:40-57.
26. Wallace K, Baron JA, Karagas MR et al. The association of physical activity and body mass index with the risk of large bowel polyps. Cancer Epidemiol Biomarkers Prev 2005;14:2082-2086.
27. Boutron-Ruault MC, Senesse P, Meance S et al. Energy intake, body mass index, physical activity, and the colorectal adenoma-carcinoma sequence. Nutr Cancer 2001;39:50-57.
28. Sato T, Takeda H, Sasaki Y et al. Increased homeostasis model assessment-insulin resistance is a risk factor for colorectal adenoma in Japanese males. Tohoku J Exp Med 2011;223:297-303.
29. Royston P. A strategy for modeling the effect of a continuous covariate in medicine and epidemiology. Stat Med 2000;19:1831-1847.
30. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558.
31. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-1101.
32. Egger M, Davey Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
33. Yu MW, Yang YC, Yang SY et al. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: A nested case-control study among men. J Natl Cancer Inst 2001;93:1644-1651.
34. Calle EE, Rodriguez C, Walker-Thurmond K et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-1638.
35. Batty GD, Shipley MJ, Jarrett RJ et al. Obesity and overweight in relation to organ-specific cancer mortality in London (UK): Findings from the original Whitehall study. Int J Obes (Lond) 2005;29:1267-1274.
36. Kuriyama S, Tsubono Y, Hozawa A et al. Obesity and risk of cancer in Japan. Int J Cancer 2005;113:148-157.
37. Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 2005; 23:4742-4754.
38. Rapp K, Schroeder J, Klenk J et al. Obesity and incidence of cancer: A large cohort study of over 145,000 adults in Austria. Br J Cancer 2005;93:1062-1067.
39. N'Kontchou G, Paries J, Htar MT et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol 2006;4: 1062-1068.
40. Samanic C, Chow WH, Gridley G et al. Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control 2006;17:901-909.
41. Ioannou GN, Splan MF, Weiss NS, et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007;5:938-945.
42. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-967.
43. Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999;116: 1413-1419.
44. Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: A populationbased cohort study. Gastroenterology 2005;129:113-121.
45. Papa S, Bubici C, Zazzeroni F et al. Mechanisms of liver disease: Cross-talk between the NF-kappaB and JNK pathways. Biol Chem 2009;390:965-976.
46. Park EJ, Lee JH, Yu GY et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010;140: 197-208.
47. Wiencke JK. Impact of race/ethnicity on molecular pathways in human cancer. Nat Rev Cancer 2004;4:79-84.
48. Weng CJ, Hsieh YH, Tsai CM et al. Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol 2010;17: 1808-1815.
49. Longato L, de la Monte S, Kuzushita N et al. Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology 2009;49:1935-1943.
50. Powell EE, Jonsson JR, Clouston AD. Steatosis: Co-factor in other liver diseases. Hepatology 2005;42:5-13.
51. Hui JM, Sud A, Farrell GC et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003;125: 1695-1704.